The mean fasting concentration of plasma thyroxine iodide (T4) in subjects with normal thyroid function (groups I and II) was 5.6 lg/100 ml, and the mean plasma T. level at 120 min was 6.6 lyg/100 ml. This difference between fasting and postTRF plasma To was significant (P < 0.001) by paired analysis. Mean fasting plasma T4 concentration in group III patients was 1.3 tsg/100 ml; after TRF a significant rise in T. concentration was not detected in this group.
The results indicate that TRF test is useful in distinguishing between primary hypothalamic and pituitary forms of TSH deficiency. In light of the evidence of TRF deficiency in eight of nine patients with idiopathic hypopituitary dwarfism, it seems likely that in these patients, other pituitary hormone deficiencies may be attributable to deficiency of their respective releasing factors.
INTRODUCTION
A large body of experimental data supports the concept of the hypothalamic neurohumoral control of pituitary hormone secretion (see reviews by Harris [1] , Reichlin [2] , McCann and Porter [3] , Everett [4] , Burgus and Guillemin [5] , and Meites [6] ). Axons arising in the basal hypothalamus pass to the median eminence, where hypophysiotropic neurosecretions are released to the primary capillary plexus of the hypophyseal portal vessels.
Thyrotropin-releasing factor (TRF)1 is the first of the hypothalamic-releasing factors whose structure is known. Burgus and associates (7) (8) (9) have reported that 'Also known as thyrotropin-releasing hormone (TRH).
The Journal of Clinical Investigation Volume 50 1971 (12) indicated an identical structure for porcine TRF. Synthetic TRF and its analogues have been prepared, and structure-activity relationships studied by both of the above groups (9, (12) (13) (14) and by other workers (15) (16) (17) . Natural and synthetic TRF is active in the mouse (14, 16, 18, 19) , rat (20) , and man (16, 17, (21) (22) (23) (24) (25) ; mean age 13 yr 7 months; group III, 9 patients (8 males, 1 female) with multiple anterior pituitary hormone deficiencies, including deficient TSH, and no demonstrable intracranial mass; mean age 15 yr 8 months.
The response of plasma growth hormone to provocative stimulation with arginine and insulin was evaluated as previously described (25, 26) . All children in group I had clearly normal responses (peak concentration of plasma HGH greater than 7.0 ng/ml in all cases), whereas all those in groups II and III were shown to be deficient in growth hormone (highest peak HGH 2.9 ng/ml and 2.0 ng/ml, respectively).
Pituitary ACTH-adrenocortical function was assessed by determination of plasma cortisol at 0 and 60 min of the insulin tolerance tests, as well as by testing with metyrapone and adrenocorticotropin (ACTH) (25, (27) (28) (29) . All children in groups I and II had normal responses, whereas six of nine children in group III were found to be deficient in ACTH (Table I ). All six of these patients had 24 hr excretion of urinary 17-hydroxycorticosteroids of less than uAU/ml, which is the lowest concentration of plasma TSH which can be measured with our assay. § Analysis by the unpaired t test revealed no significant differences in plasma TSH values of groups I and II at any time during the TRF test. Therefore, the results in groups I and II were pooled and compared with the results of group III.
1.0 mg/m2 and failed to exhibit a rise after administration of metyrapone (25) ; or when challenged with insulin, an increase in plasma cortisol (27, 29) . Plasma thyroxine iodide (T4) was measured by the method of Murphy and Pattee (30) . Mean concentration of fasting T4 was 6.1 gg/100 ml in group I and 5.0 gsg/100 ml in group II. In group III, all children had a fasting T4 concentration of less than 2.5 /Ag/100 ml before the institution of replacement therapy with thyroid hormone. Thyroid and growth hormone therapy were discontinued 3-4 wk before admission, but small replacement doses of cortisone acetate were maintained. The mean fasting concentration of plasma To in group III patients on the morning of TRF administration was 1.3 ,ug/100 ml.
Crystalline TRF,5 dissolved in distilled water which contained 1% human serum albumin, to yield a solution of 500 /Ag/ml, was passed through two Millipore filters (Millipore Corp, Bedford, Mass.) (pore size 0.45 1A) in a Swinny Adaptor. 1 ml was injected rapidly through an indwelling venous catheter and venous samples collected for determinations of plasma TSH at -15, 0, 5, 10, 20, 30, 45, 60, and 120 min, and plasma T4 at 0 and 120 min.
Radioimmunoassay of TSH. TSH was assayed by a double-antibody radioimmunoassay procedure similar to that described by Odell, Rayford, and Ross (31) and by Utiger (32) with the following modifications: A purified preparation of human TSH ' was iodinated with 'I by the method of Greenwood, Hunter, and Glover (33) . TSH, 2.5 jug, was added to 0.025 ml of 0.5 M phosphate buffer (pH 7.5) followed by 2 mCi of carrier-free 'I' of high specific activity (300 mCi/ml) then, in rapid order, 0.008 ml chloramine-T (35.2 mg/10 ml), 0.02 ml sodium metabisulfite 'Kindly supplied by Dr. Roger Guillemin, Salk Institute, La Jolla, Calif. 4Supplied by National Institutes of Health, Bethesda, Md. 'Obtained from Cambridge Nuclear Corp., Iso/Serv Div., Cambridge, Mass.
(24 mg/10 ml), and 0.05 ml of normal human serum. Labeled hormone was separated from free iodide by gel filtration with a 10 cm X 1 cm column of Sephadex G-75. Equilibration of the gel and elution from it was carried out with 0.01 M phosphate buffer, pH 7.8. Before the Sephadex column was used, crystalline bovine serum albumin, 2%, was passed through it, followed by a wash with 20 ml of the same buffer. Small portions of the labeled TSH peak were checked for damage, using 10% charcoal coated with 0.5% bovine serum albumin (34) . Damage estimated by this procedure was consistently less than 10%.
Each assay was performed within 2 days of iodination. Assays cantly, either at time 0, or at any time after TRF administration, utilizing the unpaired t test (35) . All children with idiopathic hypopituitary dwarfism and TSH deficiency had a fasting concentration of plasma TSH of less than 1.5 uU/ml (Table II) . One patient failed to exhibit an increase in plasma TSH to detectable levels throughout the period of testing. Eight of the nine patients responded to TRF (Fig. 2) with peak plasma TSH levels similar to those in groups I and II; four responded in a manner indistinguishable from normal children. In the other four, the TSH response was delayed and the initial rise in plasma TSH levels did not occur until 10, 10, 20, and 60 min, respectively. In these four patients, plasma TSH levels continued to rise at 120 min. Mean fasting plasma TSH concentration and the TSH level at 5 min after TRF administration in group III were both significantly lower than corresponding TSH levels in groups I and II. Plasma TSH level at 120 min after TRF in group III was significantly higher than the TSH concentration in groups I and II (Table II, Fig. 1 ) at that time.
The mean fasting concentration of plasma T4 in the subjects with normal thyroid function (groups I and II) was 5.6 Mg/100 ml. In 15 of 17 patients in these groups, plasma To rose after TRF; the mean level at 120 min was 6.6 Mg/100 ml. The difference between the fasting and postTRF plasma T4 was significant (P < 0.001) ( Table III) .
The mean fasting concentration of plasma T. in patients with idiopathic hypopituitary dwarfism and TSH deficiency was 1.3 Ag/100 ml. The concentration of plasma T4 did not change in the patient who failed to respond to TRF. Seven of eight patients who responded had levels of plasma T4 120 min after the administration of TRF slightly higher than fasting levels, but the difference was not significant.
Three patients experienced mild nausea or lightheadedness a few seconds after administration of TRF, but this disappeared spontaneously in less than 1 min. No other side effects were noted.
DISCUSSION
The effect of synthetic TRF on the release of TSH in adults with organic forms of hypopituitarism (for example, neoplasms arising from the hypophysis), has been described in two recent reports by Fleischer et al. (22) and Hershman and Pittman (24) . None of the patients exhibited a rise in the concentration of plasma TSH after the rapid intravenous administration of TRF.
It is now widely recognized that hypopituitary dwarfism not attributable to a mass lesion, is of heterogenous etiology (25) . We recently defined a newly recognized form of hypopituitary dwarfism associated with dysplasia (18, 22) , the low concentration of plasma T., both fasting and in response to TRF, in patients with idiopathic hypopituitary dwarfism and TSH deficiency, may permit a more sustained effect of TRF at the thyrotroph cell membrane.
Although patients with ncdrmal thyroid function (groups I and II) responded to TRF with significant increases in plasma T4 concentration, the rise in each individual patient was small. Repeated administration of TRF in multiple doses or by prolonged infusion may lead to a greater increase in the concentration of plasma T, in normal patients, or significant increases in the concentration of plasma T4 in patients with TSH deficiency who responded to TRF. However, with a single rapid injection of TRF, the small increase in plasma T4 level is not sufficiently discriminatory, so that measurement of plasma TSH is required to evaluate the response to TRF.
In a recent report, Milhaud, Rivaille, Moukhtar, Job, and Binet (17) briefly described two children with hypopituitarism who showed a rise in TSH after intravenous administration of TRF. One of these children had a craniopharyngioma, with fasting concentration of plasma TSH of 1.6 oU/ml, the other had idiopathic hypopituitary dwarfism, with fasting plasma TSH level of 5.0 /U/ml.
In light of the evidence of deficient TRF in eight of nine patients with idiopathic hypopituitary dwarfism, it seems likely that the other pituitary hormone deficiencies in these patients may be attributable to deficiency of their respective releasing factors. However, since pituitary prolactin release is restrained by a hypothalamic prolactin-inhibitory factor (PIF) (2, 4, 6) , those patients who have involvement of hypothalamic neurosecretory neurons which synthesize prolactin-inhibitory factor, would be expected to have elevated levels of serum prolactin. Hence, it may be possible to identify idiopathic hypopituitary dwarfs with primary hypothalamic involvement by detecting elevated levels of serum prolactin in contrast to a deficiency of other pituitary hormones.
We suggest that deficiency of growth hormone releasing factor and a defect at the level of the hypothalamic neurosecretory neurons may be a common cause of idiopathic hypopituitary dwarfism. Growth hormonereleasing factor, like TRF, appears to be a small polypeptide (37, 38) This work was supported in part by grants from the National Institute of Child Health and Human Development and the National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, U. S. Public Health Service.
